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Abstract
Background:
Primary infection of Toxoplasma gondii during pregnancy can be transmitted to the unborn child and may
have serious consequences, including retinochoroiditis, hydrocephaly, cerebral calcifications, encephalitis,
splenomegaly, hearing loss, blindness, and death. Austria, a country with moderate seroprevalence, instituted
mandatory prenatal screening for toxoplasma infection to minimize the effects of congenital transmission.
This work compares the societal costs of congenital toxoplasmosis under the Austrian national prenatal
screening program with the societal costs that would have occurred in a No-Screening scenario.
Methodology/Principal Findings:
We retrospectively investigated data from the Austrian Toxoplasmosis Register for birth cohorts from 1992 to
2008, including pediatric long-term follow-up until May 2013. We constructed a decision-analytic model to
compare lifetime societal costs of prenatal screening with lifetime societal costs estimated in a No-Screening
scenario. We included costs of treatment, lifetime care, accommodation of injuries, loss of life, and lost
earnings that would have occurred in a No-Screening scenario and compared them with the actual costs of
screening, treatment, lifetime care, accommodation, loss of life, and lost earnings. We replicated that analysis
excluding loss of life and lost earnings to estimate the budgetary impact alone.
Our model calculated total lifetime costs of €103 per birth under prenatal screening as carried out in Austria,
saving €323 per birth compared with No-Screening. Without screening and treatment, lifetime societal costs
for all affected children would have been €35 million per year; the implementation costs of the Austrian
program are less than €2 million per year. Calculating only the budgetary impact, the national program was
still cost-saving by more than €15 million per year and saved €258 million in 17 years.
Conclusions/Significance:
Cost savings under a national program of prenatal screening for toxoplasma infection and treatment are
outstanding. Our results are of relevance for health care providers by supplying economic data based on a
unique national dataset including long-term follow-up of affected infants.
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Abstract
Background
Primary infection of Toxoplasma gondii during pregnancy can be transmitted to the unborn
child and may have serious consequences, including retinochoroiditis, hydrocephaly, cere-
bral calcifications, encephalitis, splenomegaly, hearing loss, blindness, and death. Austria,
a country with moderate seroprevalence, instituted mandatory prenatal screening for toxo-
plasma infection to minimize the effects of congenital transmission. This work compares the
societal costs of congenital toxoplasmosis under the Austrian national prenatal screening
program with the societal costs that would have occurred in a No-Screening scenario.
Methodology/Principal findings
We retrospectively investigated data from the Austrian Toxoplasmosis Register for birth
cohorts from 1992 to 2008, including pediatric long-term follow-up until May 2013. We con-
structed a decision-analytic model to compare lifetime societal costs of prenatal screening
with lifetime societal costs estimated in a No-Screening scenario. We included costs of treat-
ment, lifetime care, accommodation of injuries, loss of life, and lost earnings that would have
occurred in a No-Screening scenario and compared them with the actual costs of screening,
treatment, lifetime care, accommodation, loss of life, and lost earnings. We replicated that
analysis excluding loss of life and lost earnings to estimate the budgetary impact alone.
Our model calculated total lifetime costs of €103 per birth under prenatal screening as
carried out in Austria, saving €323 per birth compared with No-Screening. Without screen-
ing and treatment, lifetime societal costs for all affected children would have been €35 mil-
lion per year; the implementation costs of the Austrian program are less than €2 million per
year. Calculating only the budgetary impact, the national program was still cost-saving by
more than €15 million per year and saved €258 million in 17 years.
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Conclusions/Significance
Cost savings under a national program of prenatal screening for toxoplasma infection and
treatment are outstanding. Our results are of relevance for health care providers by supply-
ing economic data based on a unique national dataset including long-term follow-up of
affected infants.
Author summary
Toxoplasma gondii is a widespread parasitic disease. In the event of primary infection dur-
ing pregnancy, this parasite can be transmitted from mother to unborn child. Clinical pre-
sentation of congenital toxoplasmosis varies from asymptomatic to life-threatening risk
for the fetus and infant and in later life. Prevention programs and screening strategies of
health care providers vary in different countries. Austria has implemented mandatory pre-
natal screening for toxoplasmosis for four decades. The screening is free of charge for fam-
ilies and costs are covered by national health care providers. Compliance with the national
program is good and outcomes for infected pregnant women and their infants since 1992
are well documented. We compared lifetime costs of screening, treatment, and follow-up
with costs in a No-Screening scenario in an economic decision-analytic model. Prenatal
screening resulted in substantial cost savings due to reduction in congenital toxoplasmosis
and consequent injuries in affected children.
Introduction
Toxoplasma gondii (T. gondii) is a protozoal parasite that infects up to 30% of humans globally,
although prevalence of infection varies widely, from 10% to 80%, among world regions and
within regions [1]. While the definitive host is the cat, sources of infection for humans include
food, the water supply, and organ transplants as well as direct contact with cat feces in the soil
and domestic litter [1–5]. Additionally and of particular concern is maternofetal transmission
during pregnancy after primary infection.
Prevalence is high in South America and tropical Africa (>50%) [6], moderate in parts of
western, central, and southern Europe (30% to 50%), and relatively low (10% to 30%) in north-
ern Europe, North America, Southeast Asia, and the Sahara [7,8]. Prevention entails adequate
cooking of meat and washing of fruits and vegetables as well as drinking water free of contami-
nation with oocysts. Educational programs for prevention, however, can only reduce infection
rates, not eliminate new infections, because most people, even those who are aware of the
infection routes, do not know the source of their infection [3,4,6]. Most people infected post-
natally have no recognized symptoms, but immune suppression due to medical conditions or
treatments can lead to serious damage to the brain and eyes as a consequence of T. gondii
infection. Infection with T. gondii that occurs during pregnancy can be transmitted to the
unborn child and may have serious consequences, before or after birth, even in apparently
asymptomatic infected newborns [9–11]. Three European countries—Austria, France, and
Slovenia—have instituted mandatory prenatal screening for primary infections of T. gondii to
minimize the harmful effects of infection on infants. This is the first systematic study of the
cost of a European national prenatal screening program to reduce congenital toxoplasmosis
(CT) and its sequelae [12].
Prenatal screening for prevention of congenital toxoplasmosis
PLOS Neglected Tropical Diseases | https://doi.org/10.1371/journal.pntd.0005648 July 10, 2017 2 / 24
Congenital toxoplasmosis, risk of maternofetal transmission, and clinical
manifestations
Women with primary infection with T. gondii during pregnancy may exhibit no symptoms,
but there is about a 50% risk of transmission to the fetus and the possibility of mild to pro-
found injury to the unborn child in untreated women [1]. The risk of maternofetal transmis-
sion increases over the course of the pregnancy, from very low risk in the first trimester to
nearly 100% in the final weeks of pregnancy. In the event of transmission, risk of injury to the
fetus varies inversely with gestational age, with the risk of profound injury greatest in the first
trimester and the possibility of mild disease or no recognized symptoms in later stages of gesta-
tion [1,6,13,14].
Consequences of CT can include retinochoroiditis, hydrocephaly, cerebral calcifications,
splenomegaly, hearing loss, blindness, and death [1,6,15,16]. In countries with prenatal screen-
ing for primary infections and consequent pre- and postnatal treatment, rates of CT and
severity of symptoms in infants are lower than in countries without screening programs or
compared to historical data before screening was initiated [7,10,17,18]. In comparison, a
recent study of children in the United States with CT who had no pre- or postnatal treatment
found that 91% of the children referred had visual and/or mental impairment by age 12 [9].
The risk of CT is complicated, however, by the diversity of genotypes of T. gondii. Type II
predominates in Europe and was thought to be the predominant genotype in North America
[6,19–21]. Recent research has identified greater diversity in US wild and domestic animals
than was previously thought [22–24]. Types I and III and atypical genotypes are more com-
mon in Central and South America [25–27]. These latter strains are more virulent and
are associated with ocular disease even when acquired postnatally by immune-competent per-
sons [28]. South American genotypes are also associated with more serious injuries in CT
[19,20,28–30].
Prevalence and incidence in Europe and prevention programs
Prevalence of infection with T. gondii varies considerably in Europe, from 7% in Norway
[31], 10% in the United Kingdom [32], 19% in Italy [33], 32% in Spain [34], 33% in Austria
[31,35,36], and 34% in Slovenia [37], to 37 to 44% in France [7,38] (all reported since 2000).
Over the past 20 years, prevalence has fallen rather dramatically in most of the high prevalence
countries coincident with national education campaigns, which have perhaps led to changes in
food preparation [7,31]. Systematic screening of pregnant women also plays an educational
role in highlighting the importance of food safety and hygiene for the health of the unborn.
Countries with high prevalence in the past similarly had high rates of primary infection in
women during pregnancy. This may seem paradoxical since the higher the prevalence among
women of child-bearing age, the higher will be the proportion of women entering pregnancy
who are immune. Since prevalence, however, increases with age, the majority of young women
are not immune and continue to be at risk, presumably with the same food preparation habits
as before.
The substantial drop in prevalence from the 1990s to the present was accompanied by a
substantial drop in maternal incidence after an initial rise [7,17]. Austria in 1974, France in
1992, and Slovenia in 1995 initiated mandatory prenatal screening programs aimed at reduc-
ing maternofetal transmission as well as the severity of injury from CT. Numerous studies
have reported that systematic prenatal screening and treatment were coincident with substan-
tial reductions in maternofetal transmission and sequelae of CT [7,10,12,13,17,18,36,37,39–
45].
Prenatal screening for prevention of congenital toxoplasmosis
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No systematic economic evaluation of those programs, however, has been published. The
countries with systematic prenatal screening and treatment programs face the paradox of suc-
cessful prevention. Now there are so few children with serious, disabling symptoms of CT that
it can appear that the risk of maternal infection does not warrant the expenditure for universal
prenatal screening programs. Health budgets are under continual scrutiny. In some countries
political currents have changed and the assumption of state responsibility for health is ques-
tioned. Moreover, there are diverse stakeholders in the decision to allocate funds to prenatal
screening or to other national health needs: the Ministry of Health, insurance funds, the Minis-
try of Education, social security administrations, and families of affected children.
The purpose of the current work is to compare the societal costs of CT under the Austrian
national program of prenatal screening for primary toxoplasmosis with the societal costs that
would have occurred in the absence of the screening program.
The Austrian national program of prenatal screening
In 1961, Thalhammer revealed a rate of CT of 78 per 10,000 live births for the Austrian popula-
tion [46]. In response, mandatory prenatal screening for toxoplasma infection for all pregnant
women was implemented in 1974 under the auspices of the national health care system
[46,47]. This prenatal screening is part of a national prevention program called “Mother-
Child-Booklet-Program” for all pregnant women and their infants through early childhood.
The costs are covered by the government and the local health insurance funds; the program is
free of charge for families.
The Austrian national program is described in detail in previous works [12,31,48]. Serologi-
cal prenatal screening is performed ideally on a bimonthly schedule, at 8, 16, 24, and 32 weeks
of gestation as well as a maternal or neonatal test for women seronegative up to the time of
birth and women who have not been tested during pregnancy. In women with proven seropos-
itivity before the current pregnancy, no further toxoplasma testing is necessary. Women who
are tested and found to have been seropositive before conception require only one test. Those
with suspected primary infection during pregnancy are tested twice. In Austria during this
screening program, the local laboratories used 9 different test methods for the detection of
IgM Toxo antibodies, each performed according to manufacturer recommendations. In the
case of primary infection in a pregnant woman or to clarify suspicious test results, blood sam-
ples were retested in the reference laboratory. The Toxoplasmosis Laboratory at the Medical
University of Vienna routinely uses the in-house Sabin Feldman dye test, immunosorbent
agglutination assay (ISAGA)-IgM (bioMe´rieux, France), VIDAS Toxo IgG Avidity (bioMe´r-
ieux, Frankreich), and PCR diagnostics for the detection of toxoplasma infections in pregnant
women and their children.
In women with primary infection, amniocentesis and polymerase chain reaction of the
amniotic fluid is recommended, but costs for those additional tests are not covered by the pro-
gram. A positive result from amniocentesis identifies an affected fetus prenatally and influ-
ences the treatment during pregnancy. The routine PCR analysis used for the B1 gene after
amniocentesis showed a sensitivity and specificity of 87.2% and 99.7%. Furthermore, the
results revealed a positive predictive value and negative predictive value of 94.4% and 99.3%
[48]. More recently, using the 529-bp PCR protocol improved sensitivity up to 100.0% [49].
Pregnant women are treated after the diagnosis of primary infection until birth, and infants
with proven or suspected congenital infection are treated during the first year of life. In cases
of CT, additional investigation, including cranial ultrasound, funduscopy, and complete blood
count, is part of the program. The screening program reached 93% of pregnant women over
Prenatal screening for prevention of congenital toxoplasmosis
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the period covered by this analysis, although the ideal schedule was not achieved for most
women [31].
The Austrian Toxoplasmosis Register
The Austrian Toxoplasmosis Register records the serology history and birth outcomes for
1,387,680 pregnant women from 1992 to 2008 [12]. All cases of CT are recorded in the Register
and thus it provides the basis for evaluating the costs of the program and pediatric outcomes
over the 17-year period. In 10% of women no toxoplasma testing was necessary due to proven
seropositivity before pregnancy. Screening confirmed additional infected women, resulting in
seroprevalence of 34.4% used in the model [31]. The Register reported 70 women with primary
infection of T. gondii and 8 cases of CT per year. The management of women and infants was
stable, as was the rate of toxoplasma infection, during the observation period. Pediatric long-
term follow-up revealed that 81% of infants with T. gondii infection did not show any clinical
signs as of May 2013. All clinical variables for infection, transmission, and outcomes in infants
are shown in Table 1.
Method
We retrospectively analyze data from the Austrian Toxoplasmosis Register for birth cohorts
from 1992 to 2008 and clinical data from pediatric long-term follow-up to May 2013 [12].
Data were recorded at the Medical University of Vienna, Austria, in coordination with local
nurses, physicians, specialists, and medical care centers. Average annual number of births was
81,628 over the 17-year period [12] and 76,547 over the last decade (www.statistik.at). We
compared societal costs of illness over the lifetimes of affected children of the Austrian national
program as it was carried out with the lifetime societal costs estimated in the hypothetical sce-
nario of Austria if it had not implemented prenatal screening in those years.
We use TreeAge Pro Suite 2015 software (TreeAge Software, Inc., Williamstown, MA,
USA) to construct a decision-analytic model. Using a societal perspective, we include the costs
of treatment, care, and accommodation of injuries projected over the lifetimes of affected chil-
dren, and lost productivity that would have occurred in a No-Screening scenario with the
actual costs of screening, treatment, projected lifetime care and accommodation, and lost pro-
ductivity in Austria for all of the children in the Register from 1992 to 2013.
The current work follows a template established in a decision-analytic model for a hypo-
thetical prenatal serologic screening program for the United States [51]. The current work is
the first to use clinical data on specific child outcomes with local costs to calculate the lifetime
costs and benefits of a mandatory national prenatal screening program as it has been carried
out over time compared to the costs that would have occurred if there had been no screening
program.
The model (decision tree) contains two kinds of variables: probabilities at chance nodes
(circles) and costs of outcomes at terminal nodes (triangles). Clinical variables are listed in
Table 1 and represent the chance of primary infection during pregnancy, fetal infection, and
pediatric clinical long-term outcomes. For the No-Screening branch, probabilities are based
on international experience reported in peer-reviewed literature and synthesized in the US
model [51]. Because this is a retrospective study dating back to 1992, the use of historical data
for the counterfactual No-Screening scenario is appropriate. The risk of fetal infection in the
No-Screening scenario is taken from the actual rate of transmission among untreated women
recorded in the Austrian Toxoplasmosis Register [12]. In the Screening branch, probabilities
for results at the 8-week screening are also derived from the literature in [51] because the
small number of cases in the Austrian Register makes a comparison unreliable. For all other
Prenatal screening for prevention of congenital toxoplasmosis
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Table 1. Probabilities.
Node Test date Clinical variable Point estimate References
1 No Screening decision
2 Prob primary infection in pregnancy 0.000845 [12]
3 Prob fetal infection 0.508 [12]
4 Prob fetal death due to CT 0.05 [50,51]
5 Prob asymptomatic CT 0.06 [1]
5 Prob visual impairment in CT 0.48 [1,52]
7 Of which mild (severe) 0.09 (0.91) [1,52]
5 Prob visual and cognitive impairment in CT 0.45 [1,52,53]
10 Of which mild (severe) 0.39 (0.61) [1,52,53]
5 Prob visual, cognitive, hearing impairment, CT 0.01 [1,52,53]
1 Screening decision
18 8 Weeks Prob IgG(+) (maternal seroprevalence) 0.344 [31]
19 Prob IgG(+) IgM(+) 0.000845 [12]
20 Prob CT (maternofetal transmission) 0.034 [1,52–54]
21 Prob asymptomatic CT 0.58 [11,13,39,43–45,55–57]
21 Prob visual impairment in CT 0.3 [11,13,39,43–45,55–57]
21 Prob visual and cognitive impairment in CT 0.095 [11,13,39,43–45,55–57]
21 Prob visual, cognitive, hearing impairment, CT 0.005 [11,13,39,43–45,55–57]
21 Prob fetal death due to CT 0.02 [50]
29 16 Weeks Prob IgG(+) (primary infection in pregnancy) 0.000845 [12]
30 Prob CT (maternofetal transmission) 0.17 [36 of 217] [12]a
31 Prob asymptomatic CT 0.61 [22 of 36] [12]a
31 Prob visual impairment in CT 0 [12]a
31 Prob visual, cognitive impairment CT (cerebral) 0.28 [10 of 36] [12]a
34 Of which requiring special school 0.5 [5 of 10] [12]a
31 Prob visual, cognitive, hearing impairment, CT 0 [12]a
31 Prob fetal death due to CT 0.11 [4 of 36] [12]a
40 24 Weeks Prob IgG(+) (primary infection in pregnancy) 0.000845 [12]
41 Prob CT (maternofetal transmission) 0.09 [36 of 398] [12]a
42 Prob asymptomatic CT 0.86 [12]a
42 Prob visual impairment CT (1 w/ hearing loss) 0.056 [2 of 36] [12]a
42 Prob visual and cognitive impairment in CT 0.056 [2 of 36] [12]a
45 Of which cerebral toxoplasmosis 0.5 [1 of 2] [12]a
45 Of which physical impairment 0.5 [1 of 2] [12]a
42 Prob visual, cognitive, hearing impairment, CT 0 [12]a
42 Prob fetal death due to CT 0.028 [1 of 36] [12]a
51 32 Weeks Prob IgG(+) (primary infection in pregnancy) 0.000845 [12]
52 Prob CT (maternofetal transmission) 0.13 [48 of 368] [12]a
53 Prob asymptomatic CT 0.79 [38 of 48] [12]a
53 Prob visual impairment in CT 0.13 [6 of 48] [12]a
53 Prob visual or cognitive impairment in CT 0.08 [4 of 48] [12]a
56 Of which cerebral toxoplasmosis 0.75 [3 of 4] [12]a
57 Of which requiring special school 0.33 [1 of 3] [12]a
56 Of which physical impairment 0.25 [1 of 4] [12]a
53 Prob visual, cognitive, hearing impairment, CT 0 [12]a
63 Prob no PCR of amniotic fluid 0.43 [12]a
66 40 Weeks Prob IgG(+) (primary infection in pregnancy) 0.000845 [12]
(Continued)
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branches of the Screening arm, the probabilities are calculated from the Austrian Toxoplasmo-
sis Register and thus represent actual Austrian experience recorded by the Toxoplasmosis Lab-
oratory at the Medical University of Vienna, Vienna, Austria [12].
Costs of serology, treatment, and lifetime costs of special care and lost productivity for
affected infants and their parents are listed in Table 2. Costs of serology, other tests, and medi-
cations are derived from recorded expenses of the Austrian program from the years 1999–
2013 and adjusted to 2012 prices. For test and medication costs we use the average of costs
reported by health insurance funds. Lifetime costs of injuries of CT include treatment, accom-
modation, special schooling, loss of earnings for affected infants, and loss of parental earnings.
Earnings are used as a proxy for the lifetime productivity that is lost by the family and the soci-
ety for infants affected by CT and their parents. Estimates of costs are derived from the litera-
ture for Austria (adjusted to costs for 2012) and, when necessary, for neighboring countries
(adjusted to Austrian costs for 2012). Direct costs and productivity losses are discounted annu-
ally at 3% for as long into the future as each cost occurs. Direct costs for medication represent
average maternal and infant treatment costs. Costs of special treatment are assigned to the
actual child outcomes in the Austrian Register [12]. Detailed explanation of cost derivation
can be found in the methodological supplement, S1 Methods. For the cost assigned to death, in
utero or neonatal, we derive a Value of Statistical Life (VSL) for Austria in 2012 using the rec-
ommendation of the OECD (Organization of European Cooperation and Development),
which is based on a meta-analysis of more than 800 studies of VSL [58]. The background on
the use of VSL and the derivation of our estimate for Austria are explained in the methodologi-
cal supplement, S1 Methods.
In addition to the costs that are assigned to each outcome as terminal nodes in the tree, we
include the costs of amniocentesis with PCR, which is assigned to the group of women with
primary infection. It is unnecessary to assign the costs to specific women because it does not
change the overall costs. In Austria over the period, 60% of women with gestational toxo-
plasma infection underwent amniocentesis. The cost of PCR, which was €363.45, was
absorbed by the local prenatal care centers. The total cost was almost €256,000. Since the deci-
sion tree calculates the cost per birth in the country, we assign the cost of PCR as overhead on
all 1,387,680 births over the period. It is expected that the cost of PCR will drop significantly in
the near future, to an estimated €100 when the testing is done routinely, reducing costs overall.
Although the women and their insurers did not bear the cost, the expense does represent a
societal cost and so we include it in the analysis.
The decision tree shows the probabilities of all possible outcomes and the costs associated
with each outcome. In Fig 1, each outcome has a conditional probability that is the product of
the probabilities along each branch. The formulas at the terminal nodes for each outcome list
the direct and indirect costs that are explained in Table 2.
Table 1. (Continued)
Node Test date Clinical variable Point estimate References
67 Prob CT (maternofetal transmission) 0.37 [18 of 49] [12]a
68 Prob asymptomatic CT 0.944 [17 of 18] [12]a
68 Prob visual impairment in CT 0 [12]a
68 Prob visual and cognitive impairment in CT 0.056 [1 of 18] [12]a
68 Prob visual, cognitive, hearing impairment, CT 0 [12]a
a These data were obtained by the Austrian Toxoplasmosis Register. This register comprises all suspected infections with T. gondii during pregnancy and
all congenitally infected infants in Austria since 1992.
https://doi.org/10.1371/journal.pntd.0005648.t001
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The method outlined above is the conventional way to calculate the lower-cost option,
including societal costs that are borne by affected infants, their families, and the economy as a
whole, regardless of who pays. There could be times, however, that a Ministry of Health or
other institution would like to know just the impact of a program on the government budget,
not societal cost. For that reason, we also calculate the cost-saving option considering only
those costs paid by government and public insurance funds, that is, omitting lost productivity
of affected children and their parents and VSL.
Table 2. Direct and indirect costs.
Variable name Description Present value in euros (2012) Source
Test and medication costs
Fundus Indirect funduscopy cost 54.26 a
InfIgGtest Infant IgG test cost 13.48 b
InfIgMtest Infant IgM test cost 17.69 b
MatIgGtest Maternal IgG test cost 6.50 b
MatIgMtest Maternal IgM test cost 6.89 b
PedCBC CBC during pediatric treatment 24.85 c
PedConsult Pediatric consultation cost* 0 a
PedCranialUltra Pediatric cranial ultrasound cost 90.71 a
PedECG Pediatric ECG cost 18.05 c
PedRx Pediatric treatment costs 12 months 160.26 d
RxNegPCR Maternal treatment costs with negative PCR of amniotic fluid 181.78 d
RxPosPCR Maternal treatment costs with positive or no PCR of amniotic fluid 178.32 d
Direct costs due to impairments
Cerebral Treatment costs for cerebral CT 30,458 e, [59]
CognMild Treatment costs for mild cognitive impairment 66,071 e, [59]
CognSevere Treatment costs for severe cognitive impairment 445,536 e, [59]
HearingMild Treatment costs for mild hearing impairment 20,924 e
SpecEdBlind Special school costs for severe visual impairment 86,239 e, [60]
SpecEdMildCogn Special school costs for mild cognitive impairment 73,699 e, [60]
SpecEdSevereCogn Special school costs for severe cognitive impairment 713,141 e, [60]
VisualMild Treatment costs for mild visual impairment 1,576 e, [60]
Indirect costs due to impairments
ChildPyLoss Productivity loss for severe cognitive impairment 561,721 e, [61,62]
ParentPyLoss Productivity loss of parents 33,940 e, [60,63]
VisualSevere Income loss and non-medical costs of severe visual impairment (for societal costs) 393,624 e, [64]
VisualSevere Non-medical costs of severe visual impairment (for budget impact only) 327,594 e, [64]
VSL Value of a statistical life 5.85 million e, [58]
Value of a statistical life (for budget impact only) 0
* The standard pediatric protocol includes 5 well-baby consultations, so there is no additional expense for infants with CT.
Sources:
a. Average for all 9 regional health insurance funds: Burgenla¨ndische Gebietskrankenkasse, Ka¨rntner Gebietskrankenkasse, Niedero¨sterreichische
Gebietskrankenkasse, Obero¨sterreichische Gebietskrankenkasse, Salzburger Gebietskrankenkasse, Steierma¨rkische Gebietskrankenkasse, Tiroler
Gebietskrankenkasse, Vorarlberger Gebietskrankenkasse, Wiener Gebietskrankenkasse;
b. Average Austrian laboratory costs, numerous payers;
c. BMGF, Austrian Federal Ministry of Health;
d. Cost of treatment for health insurance funds;
e. See methodology supplement, S1 Methods.
https://doi.org/10.1371/journal.pntd.0005648.t002
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To test the robustness of our results to variations in costs, we perform a sensitivity analysis
using an Incremental Tornado diagram varying all costs –10% and +10%, except for test costs,
which have a lower bound of €4, and VSL, which is given a range of €800,000 to €6,700,000.
The former amount represents only the discounted valuation of productivity loss over the life-
time, and the latter amount is the upper bound of the OECD estimate of VSL. (See S1 Methods
for explanation of VSL derivation.)
Fig 1. Decision tree before calculation. Tree with societal cost formulas at terminal nodes.
https://doi.org/10.1371/journal.pntd.0005648.g001
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Ethics statement
The maternal screening study was approved by the local ethics committee at the Medical Uni-
versity of Vienna, Vienna, Austria (824/2009). All adult subjects and parents of any child par-
ticipants gave their informed consent orally in person or by telephone at the time of inclusion.
The individuals were included in the nationwide toxoplasmosis register performed 1992–2008
and their oral consent was documented in the register data file. Written consent could not be
obtained, due to the fact that this was a nationwide study. The data were processed anony-
mously. The current economic study utilized anonymous data from the national screening
program.
Results
In Austria, a country with a moderate seroprevalence of T. gondii during childbearing years,
we recorded a total of 1,387,680 women giving birth between 1992 and 2008 (www.statistik.
at). Fig 2 shows the decision tree after calculation of the lower-cost option, based on the proba-
bility of each outcome and the costs associated with each. As shown in Fig 2, and summarized
in Table 3, lifetime societal costs of CT sequelae in the No-Screening scenario would have been
€426 per birth, or about €35 million for all Austrian births in one year. Total societal costs in
Austria that would have occurred without prenatal screening for nearly 1.4 million births over
the 17 years would have been about €591 million, including costs for lifelong treatment and
accommodation, as well as loss of earnings for affected children and their parents.
In contrast, prenatal screening for toxoplasma infections according to the Austrian national
program including costs of screening, maternal treatment, infant treatment, and lifetime costs
for those infants with CT sequelae amounted to €103 per birth. The total cost of the Screening
scenario, including lifetime costs of CT sequelae, was €8.4 million for all births in one year for
Austria, or €143 million for 1.4 million births in the 17-year period.
As shown in Table 3, the prenatal screening option resulted in savings of €323 per birth, or
about €26 million per year compared to No-Screening. For all births, screening saved about
€448 million in 17 years.
Adding the cost of amniocentesis with PCR for 60% of the women with primary toxo-
plasma infection during pregnancy increased the cost per Austrian birth in the period by
about €0.18, changing the difference in cost per birth of the entire screening and treatment
program by a trivial amount.
Actual program costs and the cost of CT for an affected child
The TreeAge program calculates all of the costs that occur in each scenario—the counterfac-
tual (No screening) compared to all actual lifetime costs in Austria resulting under the screen-
ing scenario. Thus the TreeAge program attributes costs to the Screening scenario that result
from treating infants who are infected despite the program, including those whose mothers
were not screened or were screened inadequately, with the lifetime costs of follow-up, accom-
modation, and parental work time lost. In Austria, if there were no screening program, one
must assume that the state would provide health care for a child born with, or who later devel-
ops, CT symptoms. So the costs of diagnosing and caring for a symptomatic infected child are
not really costs of the screening program itself. They would occur (and in much larger num-
bers) without the national screening. The €8.4 million a year under the Screening scenario
represents the costs of the screening program plus the lifetime societal cost for the affected
children born during the 17-year period.
The screening program itself entails very little cost. It includes only testing all pregnant
women (except those already known to be seropositive) and treating women with primary
Prenatal screening for prevention of congenital toxoplasmosis
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Fig 2. Decision tree after calculation. Tree showing results for societal costs.
https://doi.org/10.1371/journal.pntd.0005648.g002
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infection. It also would include the cost of treating the very few asymptomatic infected infants
because without screening they would be missed, but with screening, they would be treated
from birth. Under the screening program, there have been 70 incident infections in mothers
per year. Without treatment, there would be a fetal infection rate of 0.508 [12] and a probabil-
ity of asymptomatic CT of 0.06 [1]. Thus, there would be two asymptomatic infected newborns
treated per year because of the screening program who would have been overlooked without
screening (70 x 0.508 x 0.06 = 2.10). Costs for each of those children would be: 5 infant IgG
test, 5 infant IgM test, pediatric treatment, CBC, ECG, cranial ultrasound, and 17 fundusco-
pies, which amount to €1,372.
The costs of the screening program, shown in Table 4, total approximately €1.9 million per
year for all pregnancies, or €25 per pregnancy. A new diagnostic appears likely with a test cost
of about €4. Recalculating with a test cost of €4 would reduce the total cost of prenatal screen-
ing and maternal treatment from about €1.9 to about €1.2 million (calculation not shown).
The costs of the screening program can be compared to the cost of caring for a child whose
mother is not treated. The costs for individual services and productivity losses are listed in
Table 2, but each symptomatic child generates multiple kinds of costs. In the tree before roll-
back (calculation), Fig 1, all the costs for an individual child for each outcome are listed at the
terminal node. For example, in the No-Screening scenario, a child with severe visual, cognitive,
and hearing impairment (Terminal node #14 in Fig 1) will incur the following costs (assuming
symptoms at birth that lead to testing, treatment, and follow-up care): 5 infant IgG tests, 5
infant IgM tests, pediatric treatment, CBC, ECG, cranial ultrasound, and 17 funduscopies, as
well as the direct costs and productivity losses for child and parents associated with severe
visual, cognitive, and hearing impairment, and special education costs.
Fig 2 (Terminal node #14) shows the sum of those costs. The lifetime cost for one child
with severe visual, cognitive, and hearing impairment is €1.8 million (€1,778,210). Thus the
costs of the entire screening program for one year are nearly the same as the potential costs for
Table 3. Results.
Societal costs (euros) Budgetary costs (euros)
Scenario Cost per birth Cost for all births
in one year
Costs for all births
1992–2008
Cost per birth Cost for all births
in one year
Costs for all births
1992–2008
No Screening 426 34,756,486 590,860,267 219 17,905,970 304,401,485
Screening 103 8,422,401 143,180,822 33 2,711,690 46,098,730
Saving 323 26,334,085 447,679,445 186 15,194,280 258,302,755
https://doi.org/10.1371/journal.pntd.0005648.t003
Table 4. Annual cost of the screening program.
Category Number affected Unit cost euros (2012) Total cost euros (2012)
Average annual number of pregnancies since 2000 76,547
minus 10% of women already identified IgG+ 7,655
Women needing initial IgG 68,892 6.50 447,800
Women needing IgM (assuming 34% prevalence minus 10% identified) 18,370 6.89 126,570
Women IgG– needing 4 more tests 50,520 4 x 6.50 1,313,550
Primary infections requiring treatment 70 180 12,600
Amniocentesis cost 42 363.45 15,265
Asymptomatic CT newborns tested and treated 2 1,372 2,744
Total cost of prenatal screening and treatment €1,918,529
https://doi.org/10.1371/journal.pntd.0005648.t004
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a single severely affected child whose mother was not treated. A child with only severe visual
impairment generates costs of €482,811 (at terminal node #9). The costs for four such children
exceed the annual cost of the screening program. Without prenatal treatment, more than 90%
of infected children have been found to have some form of serious impairment [1,9,52,53].
Prenatal screening with pre- and postnatal treatment as needed prevents or mitigates most
injuries.
Austria has 70 primary infections per year [12]. If we assume 50% maternofetal transmis-
sion without prenatal treatment, as seen in Austrian women who were not treated [12], that
would be 35 cases of CT each year, rather than the 8 cases per year under the treatment pro-
gram, with symptoms ranging from mild visual impairment to fetal death. Because the model
calculates costs on a population basis, the cost of €426 in the tree is a cost per Austrian birth,
which is multiplied by the number of births, resulting in potential costs of €35 million for the
35 children who would be infected under the No-Screening scenario. The screening program
costs €1.9 million per year while the societal costs of the No-Screening scenario are €35 mil-
lion per year.
It is useful to see these costs in relation to overall Austrian government spending and Gross
Domestic Product (GDP). The annual cost of the screening and treatment program is 0.007%
of total Austrian public spending on health and 0.003% of overall Austrian government spend-
ing. The annual cost of the program is 0.0006% of Austrian GDP (Derived from data at www.
focus-economics.com/country-indicator/austria/gdp-eur-bn; World Development Indicators,
www.wdi.worldbank.org).
Budget impact
Calculating just the impact on the Austrian public budget—that is, omitting the lifetime costs
of lost earnings that fall on affected children, their families, and society, and VSL for fetal and
infant deaths, we find that the maternal screening program is still cost-saving. As seen in Fig 3,
and summarized in Table 3, expenditures by government and government-sponsored insurers,
based on Austrian experience over the period 1992 to 2008, cost €33 per birth compared to an
estimated €219 per birth if the prenatal screening program had not been implemented in Aus-
tria. (As explained above, this overstates the budgetary cost of the screening program itself
because it includes diagnosis and care of children who would be cared for under the Austrian
health care system even without a screening program.) Even from the extremely narrow bud-
getary perspective, the Austrian national program has more than paid for itself in reducing the
costs to the state and state-sponsored institutions of treating and educating children injured by
CT by €186 per birth for 1.4 million births over the period. That amounts to a total budgetary
saving of more than €258 million, or more than €15 million per year.
Sensitivity analysis
Results of the sensitivity analysis show that the savings both to society and to the government
budget are robust to variations in all costs. Varying costs by ±10% had a trivial effect on cost
per birth in the No-Screening and Screening scenarios and consequently on the savings that
result from screening, for both the full societal cost and for the public budget. Fig 4 shows an
Incremental Tornado Analysis from the societal perspective. The x axis shows the difference in
costs per birth between the No-Screening and Screening scenarios with an Expected Value
(EV) of €323. The horizontal bars show the full variation in the Expected Value (savings per
birth) resulting from the range of values for each cost parameter. Both Fig 4 and Table 5 dem-
onstrate the trivial impact on the large savings that result from screening. The variation in VSL
had the greatest effect on costs, but even then the difference between low and high values for
Prenatal screening for prevention of congenital toxoplasmosis
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Fig 3. Decision tree for budget impact. Tree showing results, budget impact.
https://doi.org/10.1371/journal.pntd.0005648.g003
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savings was only €56 and the savings from screening never fell below €275 per birth. Fig 5
shows the one-way sensitivity analysis on VSL in the societal model, which again demonstrates
that whether one includes only the loss of earnings (€800,000) or the upper bound of the
OECD estimate for VSL (€6.7 million), there is little impact on the savings derived from the
screening program, showing the same minimum savings of €275 per birth seen in Fig 4 and
Table 5.
Fig 6 shows the Incremental Tornado Analysis for the Budget impact. The Expected Value,
that is savings per birth, is €186. The variation in savings per birth never exceeds €17 and the
minimum savings from the screening program for the budget is never less than €178 per
birth, as seen also in Table 6.
Discussion
In this retrospective study we compare the costs for a national program of prenatal screening
for T. gondii with a No-Screening scenario for Austria, a country with moderate seroprevalence
Fig 4. Incremental tornado sensitivity analysis, societal perspective.
https://doi.org/10.1371/journal.pntd.0005648.g004
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in women of childbearing-age and 1,387,680 births over the years 1992 to 2008. There have
been few economic analyses of CT-prevention programs [51,65]. To our knowledge this is the
first report of an economic decision-analytic model incorporating surveillance data from preg-
nancy through long-term pediatric follow-up for an entire nation over nearly two decades of
observation. Thus our data are of special interest for physicians, health care providers, and pol-
icy makers in considering the implementation of a prevention program for CT.
The substantial reductions in primary infection, maternofetal transmission, and fetal and
child injuries resulting from T. gondii infection during the implementation of the Austrian
prenatal screening program from 1992 to 2008 have been reported elsewhere [12]. In the cur-
rent work, our major finding demonstrates that a national program of prenatal screening and
treatment to prevent congenital toxoplasmosis or reduce clinical symptoms in affected infants
is cost-saving for governmental health care providers and for Austrian society. Under the Aus-
trian national prenatal screening program, total societal savings are €323 per birth. Conse-
quently, the screening program saved about €448 million in costs to Austrian society for the
birth cohorts from 1992 to 2008. Even in narrowly budgetary terms, the prenatal screening
program has saved the Ministry of Health, the Ministry of Education, and government-spon-
sored insurance funds €186 per birth, or more than €258 million over the period, averaging
more than €15 million a year, because of injuries prevented in children of women with pri-
mary toxoplasma infection. Even large variations in all costs make little difference in results.
This is not surprising given the profound injuries that can occur without treatment and the
low cost of the intervention.
Table 5. Incremental tornado risk report, societal perspective: Savings from screening.
Variable Variable range (euros)
Savings from screening
Low (euros) High (euros) Spread (euros)
Value of statistical life for fetal or infant death 800,000 – 6,700,000 274.61 330.68 56.07
Special school costs for severe cognitive impairment 641,827–784,455 314.33 330.88 16.55
Income loss and non-medical costs of severe visual impairment 354,262–432,986 315.59 329.62 14.02
Productivity loss for severe cognitive impairment 505,549–617,893 316.09 329.12 13.03
Maternal IgG test cost 4–7 320.80 331.66 10.86
Treatment costs for severe cognitive impairment 400,982–490,090 317.44 327.77 10.34
Special school costs for severe visual impairment 77,615–94,863 321.07 324.14 3.07
Maternal IgM test cost 4–8 322.22 323.60 1.38
Special school costs for mild cognitive impairment 66,329–81,069 322.19 323.03 0.84
Productivity loss of parents 30,546–37,334 322.21 323.00 0.79
Treatment costs for mild cognitive impairment 59,464–72,678 322.44 322.77 0.34
Treatment costs for cerebral CT 27,412–33,504 322.47 322.74 0.27
Infant IgM test cost 4–19 322.59 322.75 0.16
Infant IgG test cost 4–15 322.59 322.71 0.12
Treatment costs for mild visual impairment 1,418–1,734 322.55 322.66 0.11
Maternal treatment costs with no CT 164–200 322.58 322.63 0.05
Indirect funduscopy cost 49–60 322.58 322.63 0.05
Pediatric cranial ultrasound cost 82–100 322.59 322.62 0.04
Maternal treatment costs with CT 160–196 322.59 322.62 0.02
Pediatric treatment costs 12 months 144–176 322.60 322.61 0.02
Treatment costs for mild hearing impairment 18,832–23,016 322.60 322.61 0.02
CBC during pediatric treatment 22–27 322.60 322.61 0.00
Pediatric ECG cost 16–20 322.61 322.61 0.00
https://doi.org/10.1371/journal.pntd.0005648.t005
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Even in a country where prevalence is falling due to greater awareness and success of pri-
mary prevention, prenatal screening is needed. Lower prevalence means that more women
enter pregnancy susceptible to infection. Since seroprevalence increases with age, women in
their childbearing years are among the vulnerable population that has grown over the past
decades as prevalence has declined.
Under the Austrian national program of prenatal screening, there has been a dramatic
reduction in maternofetal transmission of T. gondii and in the degree of injury in affected chil-
dren compared to historical data before implementing the prenatal screening [46,47]. Interest-
ingly, the Austrian Toxoplasmosis Register shows even greater success in child outcomes than
observed in France even though the French protocol mandates monthly testing, compared
to the Austrian program of bimonthly testing [12]. It seems, however, that in Austria, while
women are attending prenatal checkups, most are not receiving the recommended number of
blood tests for primary toxoplasma infection [12,31,35]. Education of women and obstetric
staff should be a relatively inexpensive solution that would improve even further the success of
the Austrian CT-prevention program and increase the cost saving beyond what we have mea-
sured based on actual experience.
Further examination of the Austrian data demonstrates that 49% of amniocentesis testing
was unnecessary and was not based on a primary infection during pregnancy [48]. Such testing
is expensive and brings unnecessary risk to the unborn and anxiety to parents. Ongoing educa-
tion for gynecologists should help to eliminate this unnecessary cost and risk.
In sum, while the Austrian prenatal screening protocol to minimize the effects of primary
infections of T. gondii during pregnancy is cost-saving, additional cost saving could be
achieved by enhancing the education of obstetric staff. There is a need to increase the number
of susceptible women who receive the recommended number of screening blood tests at the
Fig 5. One-way sensitivity analysis on value of statistical life.
https://doi.org/10.1371/journal.pntd.0005648.g005
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recommended intervals. There is also a need to use amniocentesis only when indicated by
proven primary infection during pregnancy.
Challenges facing prevention programs
Successful screening and treatment programs, such as Austria’s, face two challenges, both of
which derive from their success. As with other public health programs, the European prenatal
screening programs and education campaigns confront the paradox of success. People do not
see or hear about infants affected by CT as they did in the past when infant deaths or profound
brain injuries and visual impairment of varying degrees were more common, due to high rates
of CT. Prevention programs only seem expensive in the absence of disease. In the face of bud-
get pressure, the absence of infants with injuries of CT can be misunderstood to mean there is
no longer a risk. On the contrary, it has taken two decades of successful prenatal screening and
treatment to make the risk invisible. Moreover, the success of education programs in reducing
prevalence in the population, while it may protect women by making them more aware of the
Fig 6. Incremental tornado sensitivity analysis (budget impact).
https://doi.org/10.1371/journal.pntd.0005648.g006
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risk of eating undercooked meat and unwashed fruits and vegetables, actually creates a larger
population of women still at risk of infection, and particularly so since even the water supply is
a source of infection in some regions.
The second challenge to the prenatal screening programs comes from the methodological
debate over the validity of observational studies versus randomized controlled trials as the evi-
dence base for interventions. Numerous authors have suggested that the question of efficacy
of prenatal screening and treatment can only be adequately answered with randomized con-
trolled trials (RCTs) [13,39,66,67]. RCTs, however, pose an insurmountable ethical problem in
countries where prenatal screening has been associated with significant improvement in out-
comes for infants whose mothers were treated prenatally. An RCT requires equipoise, which is
lacking in countries with successful screening programs (Austria, France, and Slovenia, for
example) and in countries with similar epidemiology and access to care. Without equipoise, it
is doubtful that one could construct an ethical trial that would require random assignment of
some pregnant women to denial of a treatment with demonstrated efficacy [6,7]. Blinding
could be incompatible with informed consent. It is also unlikely that such trials would have
sufficient power because, with informed consent, few parents would be likely to choose not to
medicate. The resulting selection bias would also invalidate the results of the trial. This ethical
question is not unique to prenatal screening programs for CT. Interventions to reduce smok-
ing, for example, were implemented based on observational data. Any RCT assigning partici-
pants to smoking would not have passed ethical review. It has been impossible to construct
valid RCTs for treating sexually transmitted diseases to reduce HIV incidence because obser-
vational studies and an earlier trial demonstrated that such treatment is beneficial [68]. Simi-
larly, any other effective treatments for cofactor infections cannot ethically be withheld from
controls [68,69]. Observational and historical data from Austria, France, and Slovenia, and
Table 6. Incremental tornado risk report, budget impact: Savings from screening.
Variable Variable range (euros)
Savings from screening
Low (euros) High (euros) Spread (euros)
Special school costs for severe cognitive impairment 641,827–784,455 177.86 194.41 16.55
Non-medical costs of severe visual impairment 294,835–360,353 180.30 191.97 11.67
Maternal IgG test cost 4–7 184.33 195.19 10.86
Treatment costs for severe cognitive impairment 400,982–490,090 180.97 191.31 10.34
Special school costs for severe visual impairment 77,615–94,863 184.60 187.67 3.07
Maternal IgM test cost 4–8 185.76 187.13 1.38
Special school costs for mild cognitive impairment 66,329–81,069 185.72 186.56 0.84
Treatment costs for mild cognitive impairment 59,464–72,678 185.97 186.31 0.34
Treatment costs for cerebral CT 27,412–33,504 186.01 186.27 0.27
Infant IgM test cost 4–19 186.12 186.28 0.16
Infant IgG test cost 4–15 186.12 186.24 0.12
Treatment costs for mild visual impairment 1,418–1,734 186.09 186.19 0.11
Maternal treatment costs with no CT 164–200 186.11 186.17 0.05
Indirect funduscopy cost 49–60 186.11 186.16 0.05
Pediatric cranial ultrasound cost 82–100 186.12 186.16 0.04
Maternal treatment costs with CT 160–196 186.13 186.15 0.02
Pediatric treatment costs 12 months 144–176 186.13 186.15 0.02
Treatment costs for mild hearing impairment 18,832–23,016 186.13 186.15 0.02
CBC during pediatric treatment 22–27 186.14 186.14 0.00
Pediatric ECG cost 16–20 186.14 186.14 0.00
https://doi.org/10.1371/journal.pntd.0005648.t006
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perhaps even comparative data from the United States, have eliminated the equipoise neces-
sary for an ethical RCT of prenatal screening and treatment for primary infection of T. gondii.
The European screening programs for CT have had noteworthy success, reducing the number
of deaths and profound injuries in affected infants. That success itself in reducing preventable
suffering and death commends the programs for continuation. The cost savings for national
health care systems and society at large reinforce the argument for continuation.
CT is a health problem worldwide and it is not possible to eliminate all sources of infection
for pregnant women, nor is a vaccine likely to be developed in the near future. There are, how-
ever, successful CT-prevention programs that are reducing clinical effects of CT and saving
money for national health administrations and cost to society.
Limitations
Our results understate the benefits of following the Austrian national program because the
costs associated with injuries to infants whose mothers were not tested in accordance with the
protocol are attributed to the screening scenario [31]. If those mothers had been tested on
schedule, the injuries in the infants would most likely have been fewer and less severe, as was
the case for the infants tested on schedule. Another source of overstatement of costs of actual
Austrian practice is that we show the direct costs of ideal compliance with the protocol in
obstetric visits, including the cost for all susceptible women having five tests, whereas, in prac-
tice, 97% of women had fewer than three tests. With fewer tests, that also means shorter treat-
ment and lower treatment costs than the ideal. The average time between tests was 14 weeks,
rather than the prescribed eight weeks. For two women whose infants were profoundly
affected, the time between tests was 19 weeks [31]. If Austrian practice were in full compliance
with the protocol, actual direct costs of screening and prenatal treatment would have been
slightly higher, but the costs of treatment and accommodation of infants injured by CT and
the loss of their productivity and that of their parents would have been substantially lower
because fewer infants would have slipped through the screening process. The costs of screening
and preventive treatment are negligible compared to the costs of treatment and accommoda-
tion for infants whose injuries are not prevented. Net benefits strongly favor screening.
Conclusion
As demonstrated by the Austrian national program, prenatal screening and treatment result in
substantial cost saving, both from the conventional societal perspective and even from the narrow
perspective of budgetary impact. Results in both cases are robust to wide variations in parameter
values. Our data show the positive economic value of such a prevention measure. In summary,
our findings of this economic analytic-decision model represent an important base for the discus-
sion regarding implementation or continuation of prenatal screening for toxoplasma infection.
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S1 Methods. Explanation of decision tree, clinical variables, and costs, with detailed 
identification of sources. 
Prusa AR, Kasper DC, Sawers L, Walter E, Hayde M, and Stillwaggon E. Congenital 
toxoplasmosis in Austria: Prenatal screening for prevention is cost-saving. 
This decision analysis finds the lower-cost or cost-saving option. It is essentially a benefit-cost analysis in 
which the benefits are the savings to society and to the government budget. 
Part A: Probability and cost variables in decision tree 
Each node in the tree is numbered as {number} to guide the reader through the tree. Node numbers are 
indicated in Table 1, column 1, in the article. 
{1} Decision: No screening v. Screening. In the No Screening arm, all infections and injuries are 
discovered at birth or in infancy, except fetal death. It is assumed that there is no prenatal screening or 
there is haphazard screening. All infants with CT, however, are treated; society takes on the costs of 
accommodating injuries, such as special schooling, and bears the societal costs of lost productivity.  
{2} Risk of primary infections in mothers, taken from the Austrian Toxoplasmosis Register, 1992–2008 
[1]. 
{3} Risk of mother-to-child transmission, taken from Austrian data, almost identical to the international 
estimate used in the US study [1,2]. The range of estimates considered in the US study was 0.36 to 0.61, 
and the intermediate value of 0.50 was used. In the present work, we are evaluating the actual Austrian 
experience. In untreated women in Austria, the rate of congenital transmission was 0.508, which is 
appropriate for the No-screening scenario. 
{4, 5, 7, 10, 13} The probabilities are taken from the US study [2], which incorporated all the relevant 
international data (European and US). There are insufficient data from the Austrian experience on 
untreated children; the decades of data from other sources give us a better picture of the outcomes for 
untreated mothers and children. 
{6} A child who has no symptoms (under the no screening scenario) will generate no costs beyond the 
usual well-baby care. 
{8, 9, 11, 12, 14} These costs reflect the costs of monitoring and treating a symptomatic child, based on 
Austrian practice and estimates. They are net of routine well-baby care, for example routine visits in the 
first year. 
{8} Visual mild = VisualMild 
For mild visual disability, we assume no productivity loss for affected children or their parents. 
The derivation of cost estimates is explained below in Part B. 
{9} Visual severe = VisualMild + VisualSevere + SpecEdBlind 
For children with severe visual disability, we use treatment costs for mild visual impairment, VisualMild, 
plus non-medical direct costs and productivity losses derived from Lafuma et al. [3], which includes child 
income loss and parent productivity loss. 
{11} Visual and cognitive mild = VisualMild + CognMild + SpecEdMildCogn 
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{12} Visual and cognitive severe = VisualMild + CognSevere + SpecEd SevereCogn + ParentPyLoss 
+ ChildPyLoss 
In order not to double count home care, parent productivity loss, and other non-medical costs for a child 
with severe visual and cognitive disability we use treatment costs for mild visual disability. Severe 
cognitive disability entails a child productivity loss, that is, the child is unable to work upon reaching 
working age, and a parent productivity loss, neither of which is included in Gustavsson et al. [4] costs for 
“Mental retardation,” which is used to calculate CognSevere. 
{14} Visual, cognitive, and hearing severe = VisualMild + CognSevere + HearingMild + SpecEd 
SevereCogn + ParentPyLoss + ChildPyLoss 
{15}, {26}, {38}, {49}, {62}, {73} Fetal or neonatal death = VSL 
The cost of a fetal or neonatal death is the Value of a Statistical Life, discussed below in Part C. 
{16, 17} No costs result for these outcomes. 
{18} If all women are screened at 8 weeks gestation, then 34% (0.344) will be IgG+, based on Austrian 
prevalence.  
{19} Of these IgG+ women, most will have been infected before pregnancy, and 0.000845 of women will 
have new infections (IgM+). 
{20, 21} Because there were so few cases in the Austrian data, the international estimate is used [2].  
{22 to 26} For each possible outcome, the costs are listed at the terminal node (the triangle). The pattern 
is the same throughout. For example, at {22}, for a child with CT whose mother’s serology indicates that 
she was infected during the first 8 weeks of gestation and who is asymptomatic, the costs will be 1 
maternal IgG test, 1 maternal IgM test, 5 infant IgG tests, 5 infant IgM tests, pediatric treatment for a 
year, pediatric CBC, one ECG, one cranial ultrasound, 17 funduscopies beyond routine care, and the cost 
of maternal treatment when CT is identified (RxPosPCR). In {23 to 26} there are additional costs due to 
symptoms, including death {26}. 
{23 to 74} Loss of child productivity is not included in the screening (with pre- and post-natal treatment) 
arm because, in Austria, in all cases the children are able to work upon reaching working age. The 
Austrian Toxoplasmosis Register [1] records the specific effects in each child, so each node in the 
screening branch is tailored to actual experience of the children affected. 
{23}, {33}, {44}, {55}, {70} Visual = VisualMild 
Visual impairment is mild in all children who are treated. 
{24} Visual and cognitive mild = VisualMild + CognMild 
Visual and cognitive impairment is mild in all children who are treated. 
{25} Visual, cognitive & hearing with cerebral CT = VisualMild + CognMild + HearingMild + 
Cerebral 
{27} In this branch, there is no CT. The mother is treated for the No CT case (RxNegPCR), that is, with a 
negative PCR of amniotic fluid. The child is monitored for the first year and has one funduscopy at birth. 
There is no ECG (ECG is needed before treating infants with spiramycin and these infants will not be 
treated).  
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{28} When the mother is found to have been infected before pregnancy, the only cost is for maternal IgG 
and IgM. Note that in the rest of the tree, there are no maternal IgM tests because only at the 8-week test 
is there uncertainty about whether the maternal infection occurred during pregnancy. In actual cases, not 
all mothers are tested at 8 weeks. If their first test occurs at 16 weeks, they might have an IgM test, but 
there is no way to include that detail of non-compliance in the model. The screening costs are trivial and 
unimportant for determining the lower-cost outcome. The potential injuries to the child from delayed 
testing, however, are very important. As we note in the article, the model both understates and overstates 
cost of best practice (full compliance) in two ways: 1) not as many screenings are conducted as we 
include in the tree (overstating actual costs of screening, but understating costs of treatment for mothers 
identified with primary infections), and 2) children suffer injuries that might have been avoided with 
better compliance, and those injuries entail costs that we do include (overstating costs of injuries if 
compliance had been optimal). 
{29} Women who are IgG– at 8 weeks are retested and 0.000845 of them will have primary infections. 
{30} Risk of fetal infection based on Austrian Toxoplasmosis Register, 36/217 = 0.17. 
{31, 34} Based on the Austrian Toxoplasmosis Register. 
{32, 33, 35, 36, 37, 38} These costs are based on Austrian protocol and specific outcomes are based on 
the Austrian Toxoplasmosis Register. 
{35} Visual and cognitive with cerebral CT and special schooling = VisualMild + CognMild + 
Cerebral + SpecEdMildCogn 
{36} Visual and cognitive with cerebral CT and special schooling = VisualMild + CognMild + 
Cerebral 
The children at nodes 35 and 36 had cerebral CT, but not all required special schooling. 
{37}, {48}, {61}, {72} Visual, cognitive, and hearing = VisualMild + CognMild + HearingMild 
{39} Only one funduscopy at birth is administered because there is no CT. 
{40} Women negative at 16 weeks are retested at 24 weeks, of whom 0.000845 have primary infections. 
{41} Based on Austrian Toxoplasmosis Register, 36/398. 
{42, 45} Based on Austrian Toxoplasmosis Register. 
{43, 44, 46, 47, 48, 49, 50} Based on Austrian costs and Austrian Toxoplasmosis Register. 
{46} Cognitive with cerebral CT = CognMild + Cerebral 
{47} Visual with physical = VisualMild +CognMild 
The children at nodes 46 and 47 have mild cerebral CT or mild visual and physical impairment. None of 
the children in the treatment arm is unable to work. 
{51} Women negative at 24 weeks are retested at 32 weeks, with 0.000845 incidence. 
{52} Based on Austrian Toxoplasmosis Register, 48/368 
{53, 56, 57} Based on Austrian Register 
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{54, 55, 58, 59, 60, 61, 62} Based on Austrian protocol and costs 
{58} Cerebral CT with special schooling = CognMild + Cerebral + SpecEdMildCogn 
{59} Cerebral CT with no special schooling = CognMild + Cerebral 
{60} Visual with physical impairment = VisualMild + CognMild 
{63} When the mother is infected late in pregnancy, there is a high risk of fetal infection. Fetal infection 
was ruled out through PCR in 57% of cases, and the children were not treated. For late-infected women 
without PCR (43%), their children were treated for one year and had a year of CBC. 
{64} High risk of fetal infection with no PCR = Children are treated as a precaution. 
{65} High risk of fetal infection with negative PCR = Children are not treated. 
{66} All seronegative or unscreened mothers are tested at birth, or the newborn is tested. For simplicity, 
both are designated as maternal test, with the same primary infection rate of 0.000845. 
{67} Based on the Austrian Toxoplasmosis Register, 18/49 were seropositive, or 0.37. 
{68} Based on the Austrian Toxoplasmosis Register. 
{69–74} Based on the Austrian Toxoplasmosis Register, the protocol, and Austrian costs 
{71} Cerebral CT = CognMild + Cerebral 
{74} The mother is not treated because the test is at the time of birth. The baby is treated for one year 
because of high risk of transmission and has one funduscopy. 
{75} The only cost for the great majority of mothers is for the 5 IgG tests. (The number of women who 
remain IgG ̄ is 1,387,680 minus 1173 primary infections.)  
Part B: Derivation of costs used at terminal nodes in decision tree 
Sources for the first 12 items in Table 2 are listed in the table. The following explains derivations of 
treatment and accommodation costs based on levels of disability and productivity losses listed in Table 2. 
When Austrian costs were not available, we used costs from nearby countries with similar health systems 
and adjusted to Austrian costs as explained below. 
Cerebral CT (treatment cost, years 0 to 4) is based on the costs for “Epilepsy” from Gustavsson et al. 
[4] Table 7, page 730. They estimated the annual cost of epilepsy per person in Austria in 2010 to be 
€6,079. We adjust Austrian costs from 2010, when the consumer price index was 109.53 to 2012 when 
the consumer price index was 116.34 (Eurostat, “HICP (2005 = 100) – annual data (average index and 
rate of change),” http://ec.europa.eu/eurostat/en/web/products-datasets/-/PRC_HICP_AIND) [5]. The 
ratio is 1.062, that is, consumer prices rose 6.2% in Austria between 2010 and 2012. Adjusting to 
Austrian prices in 2012, the annual cost is  
 €6,079 x 1.062 = €6,457. 
Since these children have relatively mild outcomes and their symptoms are controlled, we apply these 
costs only for 5 years. Total cost for 5 years discounted at 3% annually is €30,458. Our analysis estimates 
the value of a stream of economic costs into the future. Future costs are assumed to be worth less than 
current ones, so costs and benefits in the future must be weighted less than those in the near term to 
Methodology supplement, Congenital toxoplasmosis in Austria, 5 
 
determine what economists call the present discounted value. The annual rate of discount most commonly 
used in health economics is 3% [6]. 
Child productivity loss is the life-time wage loss due to severe impairment that prevents gainful 
employment. The OECD reports the mean Austrian annual wage for full-time, full-year employees for 
2012 to be €38,273, (OECD.Stat, “Average Annual Wage,” https://stats.oecd.org/Index.aspx?Data 
SetCode=AV_AN_WAGE) [7]. The mean retirement age in Austria reported by the OECD (“Ageing and 
Employment Policies – Statistics on average effective age of retirement,” http://www.oecd.org/els/emp/ 
ageingandemploymentpolicies-statisticsonaverageeffectiveageofretirement.htm) [8] is 60.5 years. The 
total wage loss from age 18 to age 60.5 discounted at 3% annually is €561,721.  
Cognitive mild (direct and indirect costs) is derived from Gustavsson et al. [4] Table 11, page 734, 
which gives annual cost per person as weighted means for all diagnoses and age groups within the 
disorder. For this category we use “Child and adolescent disorders,” which covers several developmental 
disorders, and includes direct and indirect costs. Indirect costs for this category include parent 
productivity loss. Gustavsson et al. estimate the annual cost of child and adolescent disorders for Austria 
in 2010 to be €4,391. We adjust to 2012 prices,  
 
 €4,391 x 1.062 = €4,664.  
 
The total cost of mild cognitive impairment over 18 years discounted at 3% annually is €66,071. 
 
Cognitive severe (direct costs and some indirect costs, lifetime) is based on Gustavsson et al. [4] Table 
11, page 734. Their estimate of the cost of “Mental retardation” includes direct and some indirect costs 
but does not include lifetime productivity loss for the parent or for the child upon reaching working age. 
For Austria in 2010, Gustavsson et al. estimate an annual cost of €13,404. Adjusting to 2012 prices, 
annual cost of mental retardation in 2012 in Austria is  
 
 €13,404 x 1.062 = €14,237.  
 
Life expectancy in Austria is 80.5 years (OECD, “Life expectancy has increased remarkably in OECD 
countries,” www.oecd.org/berlin/47570143.pdf) [9]. The lifetime costs of mental retardation discounted 
at 3% annually are €445,536. 
Hearing mild (treatment cost, lifetime) Hearing loss is not seen in children with CT in the absence of 
other outcomes. Even though hearing loss might be profound, we estimate the cost only for mild hearing 
loss (correctable with hearing aid) in order to avoid double counting for special schooling, parental 
productivity loss, and other treatment and indirect costs. Thus we include only the cost of hearing aids, 
which in Belgium, without subsidies, is €3,500 (Hear-it, at http://www.hear-it.org/hearing-loss-Belgium.) 
Hearing aids need to be replaced every five years (Emory University, http://www.emoryhealth 
care.org/ear-nose-throat/audiology/faq-hearing-aids.html, and Hear-it, http://www.hear-it.org/hearing-
loss-Denmark). We do not include the cost of batteries or hearing tests. We adjust for the difference in 
consumer price levels between Belgium and Austria in 2012 using Eurostat, “Comparative price levels of 
final consumption by private households including indirect taxes (EU 28 = 100),” 
(http://ec.europa.eu/eurostat/tgm/printTable.do?tab=table&plugin=1&language=en 
&pcode=tec00120&printPreview=true) [10]. Adjusting to the Austrian price level, the cost in 2012 is: 
€3500 x 0.0962 = €3,366. 
The total cost for hearing aids replaced every five years beginning at age 2 until age 77 discounted at 3% 
annually is €20,924. 
Methodology supplement, Congenital toxoplasmosis in Austria, 6 
 
Parent productivity loss (years 0 to 18) is based on estimates of mother’s work reduction from Lange et 
al. [11] Tables 1 and 2, page 1131, calculated in Walter et al. [12] Table 7.9, page 134. Walter et al. 
estimate the mother’s annual earnings loss for Germany in 2008, for children < 6 years, 6 to 10 years, and 
11 to 18 years. We adjust from German to Austrian prices for 2008 using Eurostat, “Comparative price 
levels of final consumption by private households including indirect taxes (EU 28 = 100)” [10]. Austrian 
prices were 1.0154 higher than German prices in 2008. We adjust Austrian costs to the price level in 2012 
using Eurostat, “HICP (2005 = 100) - annual data (average index and rate of change)” [5]. Austrian prices 
increased 8.45% between 2008 and 2012. 
We adjust each of the annual earnings loss estimates for Germany in 2008 to Austrian prices in 2012, as 
follows: 
 
 < 6 years:  €3,418.58 x 1.0154 x 1.0845 = €3,764.54 
 6 to 10 y: €2,084.36 x 1.0154 x 1.0845 = €2,295.30 
 11 to 18 y: €   672.34 x 1.0154 x 1.0845 = €   740.38 
 
The total parental earnings loss over 18 years discounted at 3% annually is €33,940. 
Special Ed, severe visual impairment is based on a study by Walter et al. [12] Table 7.9, page 134. 
They estimate the cost of schooling for blind children in Germany in 2008 to be €10,333 per year for 10 
years. We adjust that amount to Austrian prices in 2012 using Eurostat, “Comparative price levels of final 
consumption by private households including indirect taxes (EU 28 = 100)” [10] and “HICP (2005 = 100) 
- annual data (average index and rate of change)” [5], for an estimate of annual per-child cost of special 
schooling of 
€10,333 x 1.0154 x 1.0845 = €11,379. 
Assuming children have special schooling from age 5 to 14, total schooling cost discounted at 3% 
annually is €86,239. 
Special Ed, mild cognitive impairment is based on a study by Walter et al. [12] Table 7.9, page 134. 
They estimate annual costs of schooling in Germany in 2008 for those with mild cognitive impairment to 
be €6,126. We adjust German schooling costs in 2008 to Austrian prices in 2012 using Eurostat, 
“Comparative price levels of final consumption by private households including indirect taxes (EU 28 = 
100)” [10] and “HICP (2005 = 100) - annual data (average index and rate of change)” [5], as follows: 
 €6,126 x 1.0154 x 1.0845 = €6,746. 
The children receive 15 years of special schooling from age 4 to 18. Total costs are discounted at 3% 
annually and amount to €73,699. 
Special Ed, severe cognitive impairment is based on a study by Walter et al. [12] Table 7.9, page 134. 
They estimate the cost of schooling for children with severe cognitive impairment in Germany in 2008 to 
be €44,835 per year for 20 years. We adjust that amount to Austrian prices in 2012 using Eurostat, 
“Comparative price levels of final consumption by private households including indirect taxes (EU 28 = 
100)” [10] and “HICP (2005 = 100) - annual data (average index and rate of change)” [5], for an estimate 
of annual per-child cost of special schooling of 
€44,835 x 1.0154 x 1.0845 = €49,372. 
Assuming the children receive special schooling from age 2 to 21, total costs for 20 years discounted at 
3% annually amount to €713,141. 
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Visual mild (treatment cost only, age 0 to 18) is based on a study by Walter et al. [12] Table 7.6 and 
7.7, pages 130–131. They give estimates of treatment costs for visual impairment in children with CMV 
who were either symptomatic or asymptomatic at birth, assuming a 5% annual discount rate. Averaging 
those two estimates gives the following treatment costs of visual impairment as  
€1,258 + €1,222 = €2,480/2 = €1,240. 
To determine the treatment costs with the 3% annual discount rate that is used throughout our study, we 
calculate the annual cost of treatment, assuming that costs per year are uniform from age 0 to 18, using 
the following formula 
Annual cost   =   [1240 (1 + r)Y-1r ] / [ (1 + r)Y - 1],  
where r is the annual discount rate and Y is the year. 
The annual treatment cost that would produce a total cost of €1,240 for 18 years discounted at 5% is 
€100.03. The formula for deriving the annual expenditure from a discounted present value can be found at 
moneychimp (http://www.moneychimp.com/articles/finworks/fmpayout.htm), which also provides an 
annuity calculator (http://www.moneychimp.com/calculator/annuity_calculator.htm).  
We adjust the German costs in 2008 to Austrian prices in 2012 using Eurostat, “Comparative price levels 
of final consumption by private households including indirect taxes (EU 28 = 100)” [10] and “HICP 
(2005 = 100) - annual data (average index and rate of change)” [5], producing the following estimate of 
annual treatment costs in Austria: 
€100.03 x 1.0154 x 1.0845 = €111.25. 
Total Austrian treatment cost over 18 years discounted at 3% annually is €1,576. 
Visual severe (non-medical costs) is composed of two separate costs, the loss of earnings from severe 
visual impairment and other non-medical costs associated with severe visual impairment. These costs 
must be calculated separately since they occur at different periods over a person’s lifetime. Estimates of 
both costs are based on a study of visual impairment in four European countries by Lafuma et al. [3]. In 
Table II, page 199, they report estimated annual per person income loss from severe visual impairment in 
Germany in 2004 to be 
€3,705.14 + €137.23 = €3,842. 
The calculation of lifetime earnings loss from severe visual impairment assumes people work from age 18 
to the mean retirement age of 60.5 in Austria (OECD, “Ageing and Employment Policies – Statistics on 
average effective age of retirement”) [8]. We adjust average annual German income loss in 2004 to 
Austrian prices in 2012 using Eurostat, “Comparative price levels of final consumption by private 
households including indirect taxes (EU 28 = 100)” [10] and “HICP (2005 = 100) - annual data (average 
index and rate of change)” [5], and find annual earnings loss from severe visual impairment in Austria in 
2012 to be 
 €3,842.37 x 0.9857 x 1.18787 = €4,499. 
Total income loss for ages 18 to 60.5 discounted at 3% annually is €66,030. 
Again using Lafuma et al. [3] Table II, page 199, we determine the costs of severe visual disability other 
than loss of earnings by subtracting the cost of lost earnings from total annual, per person societal costs 
(including unmet needs) 
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 €12,783.04 – €3,842.37 = €8,940.67. 
We adjust annual German costs in 2004 of disability from severe visual impairment excluding income 
loss to estimate Austrian costs in 2012 using Eurostat, “Comparative price levels of final consumption by 
private households including indirect taxes (EU 28 = 100)” [10] and “HICP (2005 = 100) - annual data 
(average index and rate of change)” [5]. Non-medical costs arising from severe visual impairment 
excluding earnings loss in Austria in 2012 are thus 
€8,940.67 x 0.9857 x 1.18787 = €10,468. 
Total other non-medical costs excluding earnings loss for all persons with severe visual impairment age 0 
to 80.5, the expected life-span of Austrians (OECD, “Life expectancy has increased remarkably in OECD 
countries” [9]) discounted at 3% annually are €327,594. 
Total non-medical costs (including earnings loss during working years) are the sum of the two figures 
calculated above, the loss of earnings from age 18 to 60.5 and other non-medical costs incurred over the 
lifetime: 
 €66,030 + €327,594 = €393,624. 
Part C: Value of a Statistical Life  
Measures of the value of a statistical life (VSL) are routinely used in the economic evaluation of public 
policies that may lead to higher or lower mortality. As a recent publication of the Organization of 
European Cooperation and Development (OECD) put it, “policy makers are regularly devising policies 
and regulations that affect people’s risk of death and that seek to protect lives in society, and require 
methodologies for comparing the costs of reducing risk with the expected benefits in terms of lives saved. 
The benefits of prevented mortalities can be expressed in terms of a ‘Value of a Statistical Life’ (VSL), 
which represents the value a given population places ex ante on avoiding the death of an unidentified 
individual” (from the Foreword of [13]). 
There is a voluminous literature on measuring VSL in Europe and other industrialized countries [13-16]. 
Initially, the discourse over VSL typically employed a human capital approach to measuring VSL based 
on the estimated value of income over a lifetime. The human capital approach has been supplanted by the 
stated preference approach favored by most European economists and the revealed preference approach 
used by most US economists. The latter two methodologies produce substantially higher measures of 
VSL than the human capital approach. 
 
The OECD recently assessed over 800 studies that use the stated preference approach to measuring VSL 
[13]. That meta-analysis found quality-screened measures of VSL ranging between US $1.8–5.4 million 
(in 2005 US dollars) with median and mean of US $3.6 million. The OECD recommends accepting the 
mean/median figure as the “base value” to be adjusted for the purposes of estimating the VSL for the 
particular group under consideration (page 127 in [13]). They add, “when the policy that is analysed 
targets children specifically (or affects mainly children), a higher VSL for children is recommended, 
based on the available empirical evidence from the United States and Europe. VSL for children should be 
1.5-2.0 times higher than the mean adult VSL” (page 131 in [13], emphasis in original). 
 
Five studies measured VSL in Austria [17-21]. In the last quarter century, substantial progress has been 
made in the methodology of measuring VSL, and only three of the five studies were carried out since the 
1980s. Two of the recent measures of VSL in Austria lie within the OECD’s range of VSL of US $1.8–
5.4 million (in 2005 US dollars) [19,20], and the third is just below that range [21]. Rather than base our 
Methodology supplement, Congenital toxoplasmosis in Austria, 9 
 
statistical analysis on three studies, we opt to follow the OECD’s recommendation since it is based on 
hundreds of studies. 
 
We adjust OECD’s recommendation for VSL, stated in US dollars in 2005, to the price level in Austria in 
2012 using Eurostat, “Comparative price levels of final consumption by private households including 
indirect taxes (EU 28 = 100)” [10] and “HICP (2005 = 100) - annual data (average index and rate of 
change)” [5]. Exchange rate data are taken from OANDA (http://www.oanda.com/currency/average/). 
 
At present, most US economists measure VSL using a revealed preference approach based on income 
differentials among occupations with different mortality risks. Datasets that have recently become 
available in the United States allow much more precise measures of income and mortality risk by 
occupation, industry, gender, age, and other categories. The new data lead to measures of VSL that are 
typically higher than both the earlier measures using the revealed preference approach and current 
measures using the stated preference approach, which is commonly used in Europe [22]. Recent US 
government benefit-cost analyses use measures of adult VSL that range between US$6 million and 
US$10 million (in 2013 dollars), equivalent to €4.6‒€7.7 million in 2012 euros [23]. In the United States, 
several authors discourage upward adjustment of VSL for children [24]. In short, the US and European 
approaches to VSL, though they use different methodologies and different age adjustments, arrive at 
recommended measures of VSL that are remarkably similar (€5‒€6.7 million in Europe vs. €4.6‒€7.7 
million in the United States). 
 
We use productivity losses derived from the literature as explained in Part B for surviving children with 
vision, hearing, or cognitive impairment. None of those estimates is adequate for attributing a value to 
fetal or neonatal death, which is why we use VSL in those few cases [25]. 
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